Orphazyme ApS Snags $19.7M In Series A for Hsp70 Program
Danish biopharmaceutical company Orphazyme ApS raised €14 million (US$19.7 million) in a Series A financing to move its lead program, Orph-001, into the clinic. The company, based in Copenhagen, is pursuing technology related to molecular chaperone heat-shock protein 70 (Hsp70) to treat disorders known as lysosomal storage diseases (LSD) a family of more than 45 often-fatal genetic disorders with few existing treatment options.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.